The entire 10K reads like a Christmas wish list. IMO
"The Flaskworks units will only be usable in the Grade C labs, and hence are not useful until the Grade C labs have been constructed, validated and are operational. Since the timeframe for fabricating the Flaskworks units is much shorter than the timeframe for buildout of the Grade C labs (including the simplified initial Grade C lab), the Company has been holding off on proceeding with the fabrication until closer to the time when the initial Grade C lab will be operational."
Planning, plans, wishing, discussing, preparations, etc...
Intensive activities continued throughout 2024, including in Q4, in multiple areas including the following:
active engagement in the Marketing Authorization Application (MAA) review process and inspections;
planning for possible initial commercialization;
completion, in collaboration with leading clinicians, of the trial design and protocol for the pediatric brain cancer trials to fulfill the legal requirement for ****pediatric applications in connection with the MAA for the adult applications;*****
initial assessments of the specific regulatory requirements for applications for product approval in additional countries beyond the UK;
working with specialized consultants on preparations for reimbursement evaluation processes;
potential expansion of the scope of the Company’s compassionate use program through private clinics;
completion of technology transfer and process development for the DCVax-Direct manufacturing processes to meet UK regulatory requirements (with the DCVax-Direct products able to be supplied globally);
development of streamlined Grade C lab ***plan** for the Sawston facility with faster timeframe and substantially reduced capital cost;
completion of process development for a new and ***potentially enhanced version*** of the DCVax-Direct product;
design of initial DCVax-Direct clinical trials, in collaboration with leading clinicians, and completion of drafting of initial protocols for upcoming IND submissions;
***negotiations*** with multiple independent parties for potential manufacturing in the U.S.;
clinical development activities for initial applications of IP from the portfolio in-licensed from Roswell Park at mid-year;
completion of an upgraded Flaskworks machine for GMP prototypes, and ***plans *** to reduce the dimensions and footprint;
AI
